Results for: C-THR81-2405 PDF Questions with A Guaranteed Success 2024 ⚒ Easily obtain free download of “ C-THR81-2405 ” by searching on ⏩ www.pdfvce.com ⏪ 🤛Exam C-THR81-2405 Format

Heart disease associated with atrophy in MS

August 15, 2018

…nd brain atrophy in 95 MS patients (Dossi et al. Front Neurol 2018;9:487 ; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC6026666/pdf/fneur-09-00487.pdf). Overall, 29.5% of MS patients were normotensive, 52.6% were prehypertensive (SBP 120-139/DBP 80-89) and 17.9% were hypertensive (SBP >140/DBP >90); according to 2017 guidelines, 29% were normotensive, 18% had elevated BP (SBP 120-129/DBP < 80) and 53% were hypertensive (SBP >130/DBP >80)…

Exploring therapeutic inertia in multiple sclerosis

July 11, 2018

…about who is at risk of early disease worsening. Therapeutic inertia may become less common once the risks of MS are better characterized, and the probabilities of long-term benefits and risks associated with different treatment approaches are better quantified. Comment Dr. Daniel Selchen: The concept of therapeutic inertia is very important for understanding treatment dynamics associated with current MS care. Treating MS was very simple until abo…

Do injectable MS drugs still have a role?

June 12, 2018

…s frequent injection (once a week) with fewer side effects (twice a month) compared to a once-daily oral with more side effects (7 times a month). Similarly, when comparing oral and infusion drugs, a majority of respondents preferred the drug with less frequent side effects regardless of the route of administration. Numerous studies have reported on patients’ treatment satisfaction. In the MSology survey (n=32), respondents were satisfied with the…

Update on CGRP inhibitors in migraine

May 18, 2018

…3% vs. 13.7%), Two analyses demonstrated that the efficacy of erenumab was comparable in migraine patients with and without aura. The first study compared erenumab versus placebo in patients with episodic migraine with or without aura (McAllister et al. AAN 2018; abstract P4.094). The mean change from baseline in MMD with erenumab 140 mg was -3.5 with aura, and -3.8 without aura (vs. -2.1 and -1.5 with placebo). The responder rates (>50% reduction…

‘Seduced by significance” – the p-value controversy

April 18, 2018

…005;2:e124, free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC1182327/pdf/pmed.0020124.pdf). He also co-authored a survey of the biomedical literature, which found that the reporting of p-values increased from 7.3% of abstracts in 1990 to 15.6% in 2014 (33.0% in core clinical journals) (Chavalarias et al. JAMA 2016;315:1141-1148). Perhaps more telling was that the 385,393 articles reported an average of 8.9 p-values per paper, most of which w…